Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBEX-102
- Development stage
- Preclinical
- Lead developer
- Rhythm Biotherapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
RBEX-102 is a heart-derived exosome-based therapy being developed by Rhythm Biotherapeutics for the treatment of early recurrence after catheter ablation (ERAF) and post-ablation atrial fibrillation. Utilizing the company's proprietary RBEX platform, these extracellular vesicles are engineered to carry native microRNAs (miR-22-3p, miR-199b-5p, and miR-374a-5p) and surface decorin protein. The mechanism of action involves selective uptake by atrial fibroblasts, macrophages, and endothelial cells, leading to the suppression of the NLRP3 inflammasome and caspase-1 signaling pathways. This results in a reduction of pro-inflammatory cytokines IL-1β and IL-18, thereby decreasing cardiac fibrosis and inflammation and promoting the restoration of normal electrical conduction. RBEX-102 is currently in the preclinical stage of development.
02
Targets
CASP1 (Caspase-1)DCN (Decorin)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TGFB (GARP–latent transforming growth factor beta 1 complex)miR-199b-5p (MicroRNA 199b-5p)miR-22-3p (MicroRNA 22-3p)miR-374a-5p (MicroRNA 374a-5p)
Beyond the preview
Go deeper on RBEX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBEX-102.